Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

Aminolevulinic Acid 183-ingenyl angelate 16Imiquimod 9Photochemotherapy 8methyl 5-aminolevulinate 7Solutions 5LEO 43204 4Gels 4BF-200 ALA 4Fluorouracil 3Cryotherapy 3tirbanibulin 2Ointments 2Blue Light 2tazarotene 1perillyl alcohol 1cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion 1bacitracin, polymyxin B drug combination 1Therapies, Investigational 1Petrolatum 1Lasers 1Laser Therapy 1Excipients 1Diclofenac 1Cholecalciferol 1Celecoxib 1Biafine 1Benzoyl Peroxide 1Bacitracin 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Keratosis, Actinic × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡